Innovation payment schemes

Director of MTRC Oleg Borisenko participated in the session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?” at the Med Tech Forum in Dublin on the 31st of May 2023. The section was moderated by Rachele Busca (Director, HTA and Real-World Evidence, EMEACLA, Edwards Lifesciences) and panelists included Daniel Bamford (Deputy Director, Medtech and Digital, Innovation, Research and Life Sciences, NHS England) and Louisa Stüwe (Ministerial eHealth Delegation, Ministry of Health and Prevention, France). Oleg presented the summary of the report on innovative payment schemes for medical technologies, commissioned in 2022 by the European industry association Med Tech Europe to MTRC. We present a summary of the presentation.

On April 14, 2023, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2023 RIHN list.

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system for lung volume reduction under Forfait innovation program.

On May 31, 2022, the French National Authority for Health (HAS) published the final positive opinion on the coverage of the endoscopic gastroplasty with the ENDOMINA triangulation platform under the Innovation package (Forfait innovation).

On March 10, 2022, the Ministry of Solidarity and Health published an Order in the Official Journal of the French Republic, which announced the transitional coverage for the Neovasc Reducer system. This is the first device to be covered under the new transitional scheme.

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

On June 18, 2021, the Ministry of Solidarity and Health published an Order in the Official Journal of the French Republic in relation to the innovation package (forfait innovation) for the test ONCOGRAMME aimed at predicting the effectiveness of chemotherapy with regard to non-operable metastatic colorectal cancer.